To date, genome-wide association studies have implicated at least 35 loci in osteoarthritis but, due to linkage disequilibrium, the specific variants underlying these associations and the mechanisms by which they contribute to disease risk have yet to be pinpointed. Here, we functionally test 1,605 single nucleotide variants associated with osteoarthritis for regulatory activity using a massively parallel reporter assay. We identify six single nucleotide polymorphisms (SNPs) with differential regulatory activity between the major and minor alleles. We show that the most significant SNP, rs4730222, exhibits differential nuclear protein binding in electrophoretic mobility shift assays and drives increased expression of an alternative isoform of HBP1 in a heterozygote chondrosarcoma cell line, in a CRISPR-edited osteosarcoma cell line, and in chondrocytes derived from osteoarthritis patients. This study provides a framework for prioritization of GWAS variants and highlights a role of HBP1 and Wnt signaling in osteoarthritis pathogenesis.
Osteoarthritis (OA) is a chronic disease of the articulating joints, characterized by the degradation of articular cartilage, synovial inflammation, and remodeling of the subchondral bone. This leads to a debilitating impairment of joint function. OA is the most common cause of disability in adults over the age of 60, and it is predicted that by 2050, it will affect over 130 million individuals worldwide1. Genetic factors comprise ~50% of an individual’s total risk of developing the disease. A series of genome-wide association studies (GWAS) have been carried out in OA and have identified 35 independent genetic signals for disease susceptibility. Outside of OA, GWAS have successfully implicated thousands of genetic loci in a wide range of common human diseases. Most of the underlying signal is believed to derive from variation in non-coding regulatory sequences. However, because of linkage disequilibrium (LD), it has been extraordinarily challenging for the field to identify the variants that causally underlie each association.
Over the past decade, we and others developed massively parallel reporter assays (MPRAs) to increase the throughput at which regulatory sequences can be tested for functional potential2,3,4,5. An MPRA involves cloning thousands of candidate regulatory sequences to a single reporter gene, transfecting them to a cell line en masse, and performing deep sequencing of the resulting transcripts to quantify the degree of transcriptional activation mediated by each candidate regulatory sequence. MPRAs have previously been applied to characterize variants underlying eQTLs (in LCLs)6, red blood cell traits (in K562 and human erythroid progenitors/precursors)7, cancer-associated common variants (in HEK293 cells)8, and adiposity-associated common variants (in HepG2 cells9).
Here, we apply an MPRA (specifically, STARR-seq5) to quantify the relative regulatory potential of SNPs residing on haplotypes implicated in (OA), prioritizing six out of 1,605 SNPs with differential regulatory activity. The most significant SNP, rs4730222 falls within an alternative TSS of HBP1, shows differential nuclear protein binding, and leads to increased expression of an alternative isoform(s) of HBP1 in several systems.
MPRA to prioritize regulatory GWAS variants
We compiled a list of 35 lead SNPs associated with OA in Europeans via GWAS, with minor allele frequencies over 5%10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27. Each SNP represents an independent signal with p < 5e-8 (genome-wide significant; n = 20) or p < 5e-5 (genome-wide suggestive; n = 15) (Supplementary Table 1). We identified all SNPs in LD with an r2 > 0.8 in Europeans using rAggr (Fig. 1a), resulting in a list of 1,605 candidate SNPs. For the major and minor allele of each SNP, we synthesized 196 nucleotides (nt) of genomic sequence, centered on the SNP and flanked by adaptor sequences, on a microarray (230 nt oligos; Fig. 1b; Supplementary Data 1).
In order to increase quantitativeness of the assay, we modified STARR-seq by incorporating five nt degenerate barcodes during PCR amplification of array-derived oligonucleotides, i.e., prior to cloning. This modification allowed us to effectively make multiple independent measurements (unique barcode–allele combinations) of each allele in a single experiment (Fig. 1c)5. We then cloned these barcoded oligos into the human STARR-seq vector and transfected Saos-2 cells, an osteosarcoma cell line, in triplicate. Importantly, in STARR-seq, the candidate regulatory sequences are located within the transcript itself, rather than upstream of the promoter as in a conventional reporter assay (Fig. 1d). From the transfected Saos-2 cells, we extracted, amplified, and sequenced both DNA and RNA corresponding to the cloned region, and then calculated activity scores as the normalized log2 (proportion of RNA reads/proportion of DNA reads) for each barcode–allele combination (Fig. 1e, f). For all alleles with at least three independent barcodes (i.e., a barcode–allele pair in any of the three replicates), we averaged the allele activity scores to a single value. Due to bottlenecking during library construction, some alleles were under sampled and therefore excluded from further analysis. Altogether, we obtained activity scores for 2,537 of 3,210 alleles (79%; avg. 12.9 measurements per allele) (Supplementary Data 2), and activity scores for both alleles of 1,132 of 1,605 SNPs (70%; avg. 13.4 measurements per allele) (Supplementary Data 3). Enrichment scores were highly correlated between independent transfections, with Spearman rho’s ranging from 0.82 to 0.9 and Pearson r’s ranging from 0.85 to 0.93 (Fig. 2a; Supplementary Data 4).
Enrichment of regulatory marks in MPRA active sequences
We first asked whether these STARR-seq-based activity scores correlated with biochemical marks for putative enhancers. For this analysis, we looked at all major alleles with at least three independent barcodes (n = 1,254). We ranked these major alleles into quintiles, and then intersected these with data sets of biochemical marks of putative enhancers in cartilage and bone (H3K27ac in bone marrow-derived chondrocytes, H3K27ac in the human embryonic limb buds, and ATAC-seq in knee OA cartilage)28,29 (Supplementary Fig. 1). The highest scoring quintile was significantly enriched for overlap with H3K27ac ChIP-seq peaks in embryonic limb bud from E41 (2.1-fold, Bonferroni-corrected chi-square p = 0.035), E44 (2.0-fold, Bonferroni-corrected chi-square p = 0.031), and E47 (2.3-fold, Bonferroni-corrected chi-square p = 0.0039), relative to all other major alleles. While the trend remained, there was neither a significant enrichment in knee OA cartilage ATAC-seq peaks (1.7-fold) nor bone marrow-derived chondrocyte H3K27ac peaks (1.4-fold). The highest scoring quintile includes 251 genomic regions, 65 of which overlap putative enhancers from at least one data set. In contrast, the lowest scoring quintile includes 250 genomic regions, only 37 of which overlap putative enhancers from at least one data set (1.7-fold enrichment, chi-square p = 2.0e-3). Altogether, these enrichments demonstrate that at least a subset of the 1,605 genomic regions tested here correspond to enhancers in OA-relevant tissues.
To evaluate whether these enrichments were specific to bone and cartilage, we similarly tested for overlap with H3K27ac ChIP-seq peaks in H1-hESCs, HeLa, HepG2, Gm12878, K562, and HSMM cell lines. We identified significant enrichment in H1-hESC (1.5-fold, Bonferroni-corrected chi-square p = 0.0021), HeLa (1.8-fold, Bonferroni-corrected chi-square p = 0.0038), and HepG2 (1.6-fold, Bonferroni-corrected chi-square p = 0.023) cells, and non-significant trends in Gm12878 (1.5-fold), K562 (1.3-fold), and Hsmm (1.1-fold). Although weaker in magnitude than the overlap with embryonic limb bud H3K27ac ChIP-seq peaks, these trends suggest that many of the tested genomic regions are not cell-type specific.
To our knowledge, this data set is the largest functional screen for enhancers in an osteosarcoma cell line. Therefore, we asked whether we could use our data to identify TFs that contribute to enhancer activity in bone. Toward the goal of predicting the enhancer activity of the major allele, we trained a tenfold cross-validated lasso regression model that considered 853 evolutionary, biochemical, and sequence-derived features (Supplementary Data 5). The predictions of our model correlated to the observed enhancer activity scores with a Spearman rho of 0.28 (Supplementary Fig. 2A). Training the lasso regression model on the entire data set, 76 total features were selected by the model (Supplementary Data 6, Supplementary Table 2). The 30 top features, which include both histone marks and TF-binding predictions of the corresponding genomic regions, are shown in Supplementary Fig. 2B.
Differential regulatory activity of SNPs in MPRA
We next sought to ask whether any alleles are differentially active, focusing on the 1,132 SNPs for which we successfully measured activity scores for both alleles (Supplementary Data 2). Overall, activity scores for two alleles of a given SNP were highly correlated, with an overall Spearman correlation of 0.744 (Fig. 2b). This was reassuring, given that each pair of alleles was separately synthesized and cloned, and therefore present at non-identical abundances in the STARR-seq library. After correcting for multiple testing with Benjamini–Hochberg (BH) at a 10% FDR, we identified six SNPs whose alleles demonstrated significantly differential functional activity in Saos-2 cells (Fig. 2b; Supplementary Data 2). The most significant SNP, rs4730222, is located in the 5′-UTR of several non-canonical isoforms of HMG-Box transcription factor 1 (HBP1). Other significant SNPs include rs2286798 (intronic to ITIH1), rs6976 (3′-UTR of GLT8D1), rs114009236 (intronic to SUPT3H), rs80095766 (intronic to COG5), and rs6088799 (intronic to UQCC). Two pairs of the six significant SNPs are at the same loci (the ones near HBP1 and COG5, both at chromosome 7q22.3; and the ones near ITIH1 and GLT8D1, both at chromosome 3p21.1). To further validate these six SNPs, we tested each of the six in a conventional luciferase-based enhancer assay, also in Saos-2 cells. The results for rs4730222 and rs6088799 were concordant with STARR-seq results, while the results for rs80095766 also showed differential activity, but in the opposite direction to STARR-seq. The other three SNPs did not demonstrate significantly differential activity.
Three of the six SNPs (notably the three with the most significant differential expression) are predicted to disrupt protein binding by RegulomeDb, compared with 117/1,126 of the remaining SNPs (p = 1.67e-3, chi-square). rs4730222 is predicted to disrupt binding of several proteins based on ChIP-seq, including POLR2A (Supplementary Data 7). rs2286798 disrupts an En1 motif, and serves as an eQTL for WDR51A, FLJ12442, ITIH3, and NT5DC2 in lymphoblastoid cells and FLJ12442 and ITIH4 in monocytes (Supplementary Table 3). rs6976 is predicted to disrupt binding of several proteins based on ChIP-seq, including POLR2A and EP300 (Supplementary Table 4). It is also an eQTL for WDR51A, FLJ12442, and NT5DC2 in lymphoblastoid cells and FLJ12442 and ITIH4 in monocytes.
Validation and characterization of rs4730222
We chose to further characterize rs4730222 for several reasons. First, this SNP was the most significant hit from our reporter assay, with a substantial difference in activity between the two alleles (2.5-fold increased expression of the minor, disease-associated allele; BH-adjusted p-value = 8.8e-5). Second, its differential activity was confirmed by a conventional luciferase-based enhancer assay (2.02-fold, Wilcoxon matched-pairs signed rank test p < 1e-4). Third, of the six, only rs4730222 overlaps with putative enhancer marks in embryonic limb buds (H3K27ac) and osteoarthritic knee cartilage (ATAC-seq). Fourth, we had previously prioritized HBP1 as a potential target in the 7q22 osteoarthritis-associated locus based on gene expression analysis30. HBP1 is a transcriptional repressor that regulates the Wnt-beta–catenin pathway as well as superoxide production, both of which have been implicated in OA development and progression31,32,33.
rs4730222 overlaps with several marks associated with active regulatory DNA: H3K27ac (mark for active enhancers and promoters) from bone marrow-derived chondrocytes29, human embryonic limb bud at E33, E41, E44, and E4728, and ENCODE layered data; H3K4me3 (mark for active promoters) in ENCODE layered data; and ATAC-seq (mark for open chromatin) peaks from articular knee cartilage of OA patients34 (Fig. 3a). HBP1 contains several transcript isoforms, with three probable alternative promoters identified from cap-selected clones and nine validated alternative polyadenylation sites35. One of the three probable alternative promoters contains rs4730222 at position + 80 relative to the alternative transcriptional start site (TSS). We therefore hypothesized that the variant may alter expression of this or another HBP1 isoform. To test this, we first confirmed that the alternative TSS overlapping rs4730222 is utilized in Saos-2 and SW1353 cells (a chondrosarcoma cell line) with qRT-PCR with primers contained within this 5′-UTR as well as spanning to the following exon. However, despite multiple attempts, we failed to successfully amplify the isoform from the alternative TSS to the canonical stop, suggesting that the alternative TSS may belong to a truncated isoform of the HBP1 transcript. Based on PCR and Sanger sequencing, the truncated isoform is most likely ENST00000497535, which contains the alternative 5′-UTR and first two exons (Fig. 3a; Supplementary Fig. 3).
After confirming that rs4730222 is transcribed as part of a HBP1 isoform in osteogenic and chondrogenic cells (albeit not to the canonical stop), we genotyped rs4730222 in several cell lines (SW1353, Tc28a/2, Saos-2, chondrogenic progenitor cells) in hopes of identifying a heterozygous line. As SW1353 was heterozygous for rs4730222, we tested it for allelic expression imbalance (AEI) of the transcribed SNP. In all three biological replicates, we observed a significant allelic imbalance (Fisher’s exact test, p < 1e-5), with the minor allele showing a 1.3 to 1.4-fold relative enrichment in RNA/DNA compared with the major allele. This was more modest but directionally concordant with 2.5-fold enrichment of the minor allele in the reporter assay (Fig. 3b).
The OA-implicated haplotype at 7q22.3 is a ~500 -kb region of high-linkage disequilibrium, and consequently accounts for 283 of the 1,605 SNPs tested here. The observed AEI of the HBP1 alternative isoform in SW1353 cells, which are likely heterozygous for the entire OA-associated haplotype, could be consequent to any or several of these SNPs, or to other forms of genetic variation. To test whether rs4730222 causally underlies the allelic imbalance of the HBP1 alternative transcript, we introduced the minor allele of rs4730222 into Saos-2 cells, which are homozygous for the major allele, through CRISPR-mediated homology directed repair (HDR). We generated four biological replicates (i.e., independently edited cell populations), and quantified the RNA/DNA ratio of indel-free reads derived from the major versus minor allele. Similar to the SW1353 AEI (1.3 to 1.4-fold), we identified a 1.4 to 1.6-fold relative enrichment in the RNA/DNA ratio for the minor allele compared with the major allele (Fisher’s exact test, p < 1e-5; Fig. 3c). This confirms that the minor allele at rs4730222 causally underlies upregulation of the HBP1 alternative isoform.
We next sought to test whether rs4730222 is associated with different levels of the HBP1 alternative isoform in osteoarthritic tissue. To do so, we tested for AEI in chondrocytes derived from OA patients. For each of nine patients heterozygous for rs4730222, we extracted RNA and DNA and amplified and sequenced the 5′-UTR containing the SNP (three technical replicates per patient) from DNA and cDNA. Despite low cDNA concentrations and low expression of the alternative TSS, we observed an overall trend in AEI in accordance with our reporter assay and cell models (median AEI = 1.06, Mann–Whitney U-test on 9 DNA ratios vs. 9 RNA ratios, p = 0.008). Interestingly, one patient appeared to exhibit AEI in the opposite direction36,37 (Supplementary Fig. 4).
Finally, in order to test whether rs4730222 is driving differential expression through TF binding, we performed EMSA experiments using nuclear protein from both Saos-2 and SW1353. For both cell types, we identified reproducible differential binding of multiple protein complexes, with greater binding for the major, G allele (Supplementary Fig. 5).
Speculating that its effect might be on the promoter of the alternative isoform of HBP1, we subjected the same fragment containing rs4730222 from the luciferase-based enhancer assay to a conventional luciferase-based promoter assay. We once again observed significant, differential expression of the two alleles, but to our surprise the directionality of effect was opposite to that of the luciferase-based enhancer assay, the STARR-seq experiment, as well as all of the other aforementioned experiments, suggesting that in this context, the regulatory element containing the SNP acts as an enhancer rather than promoter (Supplementary Fig. 6).
In sum, multiple independent lines of directionally consistent evidence, including the STARR-seq MPRA, predicted protein binding, observations of AEI in both a chondrosarcoma cell line and OA patient chondrocytes, as well as with CRISPR/Cas9-mediated introduction of the exact allele into an osteosarcoma cell line, and finally direct demonstration of differential protein binding, all support the case for rs4730222 as having differential regulatory activity between the major and minor alleles, likely by impacting expression of an alternative isoform of HBP1. Of note, testing rs4730222 in enhancer versus promoter luciferase-based assays yielded directionally discordant results, highlighting the importance of context in reporter assays.
In summary, we set out to functionally test the regulatory effects of 1,605 SNPs that potentially underlie 35 GWAS signals for osteoarthritis. We succeeded in generating reproducible measurements of differential regulatory activity for almost three quarters of the regions tested. While this data set captures most SNPs around our GWAS candidates, due to technological limitations, it is possible that potentially causal variants in these regions were not included in our assay. The most highly active regions in our assay were ~2-fold enriched for biochemical marks associated with enhancers. Considering over 800 features, we built a predictive model of enhancer activity in Saos-2, whose predictions correlated with the observed enhancer activity scores with a Spearman rho of 0.28. Some of the top features include FLI1 and p53, which have been associated with Ewing’s sarcoma and osteosarcoma, respectively. NR2F1, a transcriptional repressor that is overexpressed in bone38, was negatively correlated with enhancer activity (Supplementary Fig. 2B). Surprisingly, the top predictor was H3K27me3, which is conventionally associated with heterochromatin. One possible explanation is that the Polycomb repressive complex 2 (PRC2), which mediates the introduction of this mark, is frequently dysregulated in osteosarcoma cell lines39. An alternative explanation is that these elements are being tested outside of their native chromosomal context, and may act as poised enhancers in the genome. A further caveat is that the cell types in which the ChIP-seq data were generated (e.g., osteoblasts and EWS502 for H3K27me3) are not identical to the cell line in which the MPRA data were generated (i.e., Saos-2).
We identified six SNPs that were reproducibly associated with differential expression in the STARR-seq assay at an FDR of 10%, three of which are predicted to alter protein binding. The most significant of these, rs4730222, resides in the 5′-UTR of multiple isoforms of HBP1, a transcriptional repressor. The minor, OA-associated risk allele of rs4730222 appears to functionally underlie increased transcriptional levels of alternative isoform(s) of HBP1. This conclusion is supported by multiple lines of evidence, including the STARR-seq MPRA, observations of AEI in both a chondrosarcoma cell line and OA patient chondrocytes, and CRISPR/Cas9-mediated introduction of the exact allele into an osteosarcoma cell line. Notably, testing a fragment containing rs4730222 in a enhancer luciferase-based assay yielded a result that was directionally concordant with all other experiments, while testing the same segment in a promoter assay yielded a directionally opposite effect. In our view, the directionality observed with the CRISPR/Cas9-mediated introduction of the exact allele takes primacy, as it reflects the native chromosomal context and furthermore isolates the SNP in question from other SNPs in linkage disequilibrium.
We further demonstrated that the SNP at rs4730222 results in differential protein binding in both osteosarcoma and chondrosarcoma cells, suggesting a mechanism for the differential expression. As we note more binding at the major G allele, which results in decreased expression of the alternative HBP1 transcript, we propose that the C allele is displacing a transcriptional repressor. There are several potential transcriptional repressors bound at rs4730222 in different cell lines based on ChIP-seq data, including ZBTB7A, YY1, MAX, GTSAP30, NFKB1, and ZBTB33. Of note, ZBTB33 has previously been noted to repress non-canonical Wnt signaling40. The full list of ChIP-seq peaks at rs4730222 identified from RegulomeDb is provided as Supplementary Data 7.
We performed our assay in Saos-2 cells, an osteosarcoma cell line. Therefore, our enrichment scores are a function of this particular trans environment. Although OA is characterized by the loss of articular cartilage, there are concurrent pathological changes to other joint tissues, including bone, making an osteosarcoma cell line relevant to OA pathogenesis41. These take the form of subchondral sclerosis and the generation of osteophytes. Furthermore, there is growing evidence that aberrant development of the joint, including in the transition from articular chondrocyte to hypertrophic chondrocyte and the subsequent ossification of the cartilage, also predisposes to OA42. Moreover, we validated the AEI and differential protein binding of our lead SNP, rs4730222 in both Saos-2 and SW1353, a chondrosarcoma cell line, suggesting that this particular finding is relevant to both bone and cartilage-derived cells.
We propose that rs4730222 is contributing to osteoarthritis by disrupting the tightly regulated Wnt signaling pathway. Wnt signaling plays a key role in joint development43, as well as in joint destruction in the form of osteoarthritis44. The Wnt pathway is tightly regulated in both bone and cartilage, in order to allow for proper joint development and homeostasis45. Too little Wnt signaling disrupts both cartilage maintenance and subchondral bone homeostasis, and contributes to OA in animal models45,46. Similarly, excess signaling also triggers disease, and leads to an OA phenotype in mice47. HBP1 acts as a negative regulator of the Wnt-beta–catenin pathway48, and therefore its altered expression secondary to rs4730222 may disrupt the tight regulation of Wnt signaling and predispose to OA.
While we demonstrate a functional role for rs4730222 on HBP1 expression, further experiments are needed to directly implicate rs4730222 in Wnt signaling and OA pathogenesis. In this work, we edited the rs4730222 allele in Saos-2 in a bulk population and differentiated the editing outcomes through sequencing. Looking forward, it will be necessary to generate monoclonally edited cell lines, e.g., in Saos-2 and SW1353, to perform further functional investigation of the role of this variant. For example, the functional consequences of the variant could be examined through transcriptome sequencing and pathway analysis, or its potential impact in Wnt signaling and/or OA pathogenesis analyzed through the TCF/LEF reporter assay or qPCR of marker genes.
We previously described reduced expression of the canonical HBP1 transcript in OA tissue, relative to healthy tissue30. However, the increased expression was not consistently linked to a specific allele, suggesting that it may be driven by a trans-activating factor, rather than a cis-regulatory element. Furthermore, our findings here pertain to an alternative isoform of HBP1, not the canonical transcript. Indeed, we do not observe AEI of the canonical HBP1 transcript, but rather only of the alternative isoform.
We speculate that the impact of rs4730222, wherein the disease-associated allele increases expression of an alternative transcript, secondarily reduces expression of canonical HBP1. One possibility is that the alternative isoform encodes a non-coding RNA with an upstream open-reading frame (uORF). This isoform of HBP1 may have a trans effect on the canonical transcript, or have its own, yet uncharacterized, function in the cell. In addition, alternative TSSs have been shown to modulate translational efficiency and tissue specificity of genes49,50. Through one or several of these mechanisms, the expression levels of this isoform might modulate HBP1 levels in certain tissues. Finally, we note that the rs4730222-overlapping isoform expressed in SW1353 and Saos-2 is a truncated version of HBP1. Therefore, it may disrupt endogenous activity of the protein, e.g. by acting as a dominant negative. Distinguishing between these mechanistic possibilities for rs4730222 and HBP1, as well as for other MPRA-prioritized OA-associated SNPs, should be a high priority for the field.
Identification and design of target SNPs
We selected SNPs that had a minor allele frequency >5% and had been reported as being associated with OA in European populations at a significance level that surpassed or approached the genome-wide threshold of <5e-8. The deadline date for inclusion was May 2017. In total, 35 SNPs were identified, each representing an independent association signal (Supplementary Table 1). We ran rAGGr on our list of 35 candidate SNPs to identify all variants with a minimum minor allele frequency > = 0.001 in linkage disequilibrium with an r2 > 0.8 in Europeans (CEU + FIN + GBR + IBS + TSI) based on 1000 Genomes, Phase 3, Oct 2014. We then filtered out any polymorphisms greater than one nucleotide, resulting in a list of 1,605 SNPs. For each variant, we extracted 196 nt of genomic sequence centered around the SNP using BEDTOOLS getfasta, and edited the SNP to create both the minor and major alleles (3,210 sequences). To each 196 nt sequence, we appended HSS_clon_F (5′-TCTAGAGCATGCACCGG-3′) to the 5′ end and DO_R6 (5′-GCCGGTCAGAATGATGG-3′) to the 3′ end. We then ordered the 3,210 sequences in duplicate as part of an Agilent 244 K 230-mer array.
We amplified our sequences off of the Agilent array with HSS_clon_F and R6_5N_HSSR (5′-CCGGCCGAATTCGTCGANNNNNCCATCATTCTGACCGGC-3′) using KAPA HiFi HotStart ReadyMix in a 50 µL reaction with 0.75 ng of DNA and SYBR Green on a MiniOpticon Real-Time PCR system (Bio-Rad) and stopped the reaction before plateauing (13 cycles). This reaction amplified our library, added a five nt degenerate barcode to each sequence, and added both adapters for cloning into the human STARR-seq vector. We purified the PCR product using a 1.5x AMPure cleanup following manufacturer’s protocol. We then ligated 6 ng of our purified PCR into 25 ng of linearized human STARR-seq backbone using the NEBuilder HiFi DNA Assembly Cloning Kit following the manufacturer’s protocol. We transformed 1.2 µL of the ligation product in 50 µL of NEB C3020 cells, grew up overnight in 100 mL of LB + Amp, and extracted the library using a Zymo Research ZymoPURE Plasmid Midiprep Kit.
We transfected 1.5 million Saos-2 cells (ATCC) with 20 µg of our library in triplicate using the Thermo Fisher Scientific Neon Transfection System with resuspension buffer R at 1250 V, 40 ms, 1 shock, with 100 µL pipettes, in triplicate. After electroporation, we added the cells to 10 -cm plates with pre-warmed media (McCoy’s 5 A with 10% FBS and 1x Pen/Strep). Forty-eight hours post transfection, we extracted both DNA and RNA from each replicate using the Qiagen ALLPrep DNA/RNA Mini Kit. DNA was eluted in 80 µL and RNA was eluted in 30 µL. RNA was treated with Thermo Fisher Scientific TURBO DNase following the manufacturer’s protocol and reverse transcribed using Thermo Fisher Scientific SuperScript III Reverse Transcriptase in a 20 µL reaction with 8 µL of RNA. For each replicate, we amplified DNA in two reactions, each with 2 µg of DNA using NEBNext High Fidelity 2X PCR Master Mix with primers HSS_NF_pu1 (5′-CTAAATGGCTGTGAGAGAGCTCAGGTACAACTGATCTAGAGCATGCACC-3′) and HSS_R_pu1 (5′-ACTTTATCAATCTCGCTCCAAACCCTTATCATGTCTGCTCGAAGC-3′), and stopped before plateauing (15 cycles). After PCR, products were purified with a 1.5x AMPure cleanup, and pooled together. For each replicate, we also amplified cDNA in two reactions, each with 10 µL of RT product in 50 µL reactions with NEBNext High Fidelity 2X PCR Master Mix with primers HSS_F_pu1 (5′- CTAAATGGCTGTGAGAGAGCTCAGGGGCCAGCTGTTGGGGTGTCCAC-3′) and HSS_R_pu1 (5′- ACTTTATCAATCTCGCTCCAAACCCTTATCATGTCTGCTCGAAGC-3′), and stopped before plateauing (18–20 cycles). After PCR, products were purified with a 1.5x AMPure cleanup, eluted in 50 µL each, and pooled together. For the cDNA samples, we performed a nested reaction using KAPA HiFi HotStart ReadyMix in a 50 µL reaction with 1 µL of the pooled outer PCR reaction with HSS-NF-pu1 and pu1R (5′-ACTTTATCAATCTCGCTCCAAACC-3′), and stopped before plateauing (7 cycles). Reactions were purified with a 1.5x AMPure cleanup and eluted in 50 µL each. Flow cell adapters and indexes were added to all DNA and cDNA reactions through an additional round of PCR using Kapa HiFi HotStart ReadyMix in 50 µL reactions with 1 µL of the first DNA PCR or 1 µL of the inner cDNA PCR using an indexed pu1_P5 primer (5′-AATGATACGGCGACCACCGAGATCTACACNNNNNNNNNNACGTAGGCCTAAATGGCTGTGAGAGAGCTCAG-3′) and an indexed pu1_P7 primer (5′-CAAGCAGAAGACGGCATACGAGATNNNNNNNNNGACCGTCGGCACTTTATCAATCTCGCTCCAAACC-3′), and stopped before plateauing (six cycles). The libraries were sequenced on an Illumina NextSeq 500/550 v2 300 cycle mid-output kit.
Analysis of STARR-seq screen
We aligned all sequencing reads to a reference fasta file of our variants using BWA mem and extracted reads from error-free molecules51. Each variant contained several different 5 nt barcodes added through PCR. We counted the number of reads from each replicate for each variant–barcode combination in the DNA and cDNA pool. If there were at least ten DNA reads and at least one RNA read, we calculated an activity score as the log2 (number of RNA reads from the variant–barcode combination normalized to the total number of RNA reads, divided by the number of DNA reads from the variant–barcode combination normalized to the total number of DNA reads). We then combined all variant–barcode activity scores from each replicate, and for any variant with at least three different measurements, we averaged the activity score for a final activity score for each variant. This resulted in activity scores for 2,537 of the 3,210 alleles. In total, 1,132 of the 1,605 variants had activity scores for both alleles. For each of the 1,132 variants with activity scores for both alleles, we tested whether the two alleles drove different expression by performing a Mann–Whitney U Test for each variant using SciPy v0.19.1 with Python v2.7.3. We then performed a BH correction with an FDR = 0.10 to correct for multiple testing.
To generate the constructs for use in the luciferase reporter gene assay, primers including either a KpnI, HindIII, or XhoI 5′ restriction were designed to amplify DNA regions encompassing each of the six SNPs. Primer sequences are listed in Supplementary Table 7. Template DNA consisted of a mix of blood DNA from 20 patients. PCR products were TOPO cloned and positive clones were selected using blue/white screening and genotyped by Sanger sequencing to identify clones containing each of the two alleles at the six SNPs. It was confirmed that no other polymorphisms were present in the cloned regions. The required inserts were then sub-cloned using restriction enzymes into either the pGL3-basic or pGL3-promoter luciferase reporter plasmid (Promega), depending upon the predicted regulatory function of the region determined from the ROADMAP Epigenome database. Positive clones were sequenced to ensure the correct sequence of the constructs.
The Saos-2 human osteosarcoma cell line (ATCC) was transfected for the luciferase assays. Twenty-four hours before transfection, Saos-2 cells were seeded at a density of 8,000 per well in a 96-well plate. Cells were transfected with 100 ng of pGL3 construct DNA and 1.5 ng of Renilla luciferase reporter vector pRL-TK (Promega), using FuGene HD transfection reagent (Promega). After 24 h, the cells were lysed, and luciferase activity was determined using a Dual-Luciferase Reporter Assay System (Promega). Luminescence was measured using a GloMax-Multi Detection System (Promega). Firefly luciferase activity was normalized to the activity of Renilla luciferase. Six technical and 5–6 biologic repeats were performed per construct. P-values were calculated using a Wilcoxon matched-pairs signed rank test.
Allelic imbalance of rs4730222 in SW1353 cells
We first genotyped several osteogenic and chondrogenic cell lines for rs4730222 (SW1353, Tc28a/2, Saos-2, chondrogenic progenitor cells) using rs4730222_sangerF (5′-TACGCAGTTCGAATGAATGGGCTC-3′) and rs4730222_sangerR (5′-AGCTACAAAAACCTGGCTGTCCAC-3′). PCR products were purified with a 1.5x AMPure cleanup and Sanger sequenced with rs4730222_sangerF.
We then tested for allelic imbalance of rs4730222 in the isoforms expressing the SNP in SW1353 (ATCC). We performed three independent DNA and RNA extractions using the Qiagen ALLPrep DNA/RNA Mini Kit. DNA was eluted in 80 µL, and RNA was eluted in 30 µL. RNA was treated with TURBO DNase and reverse transcribed with SuperScript III Reverse Transcriptase. We then amplified the 5′-UTR around rs4730222 from each DNA and cDNA sample using KAPA HiFi HotStart ReadyMix in a 50 µL reaction with 100 ng of DNA or 5 µL of cDNA with HBP1_5UTR_F_pu1 (5′-CTAAATGGCTGTGAGAGAGCTCAGAGTCCGGGCTGCGGTCACATGATG-3′) and HBP1_5UTR_R_pu1 (5′-ACTTTATCAATCTCGCTCCAAACCAGCTACAAAAACCTGGCTGTCCAC-3′), and stopped DNA reactions at 25 cycles and cDNA reactions at 32 cycles. Products were purified using a 1.5x AMPure cleanup, and flow-cell adapters and indexes were added using an indexed pu1_P5 primer and an indexed pu1_P7 primer. Libraries were spiked into a Miseq v2 300 cycle run. Reads were aligned to a fasta reference file using BWA mem, and the number of perfect reads coming from both alleles was quantified from both DNA and cDNA from each replicate.
CRISPR knock-in of rs4730222 in Saos-2 cells
rs4730222 falls within a potential Cas9 PAM site (5′-ACGCGATGAATGGCGAAAGAGGG-3′). We therefore designed a guideRNA that would target rs4730222, so that the minor-allele donor would not be re-cut. We ordered the following oligos from IDT: rs4730222_guideF (5′-CACCGACGCGATGAATGGCGAAAGA-3′) and rs4730222_guideR (5′-AAACTCTTTCGCCATTCATCGCGTC-3′) and followed the Zhang lab protocol to clone them into the px458 plasmid (SpCas9–2A-EGFP and single-guide RNA)52.
We created our donor vector in two steps. First, we amplified a 1,459 -bp region around rs4730222 with the following primers, which also append 16 -bp homologous sequence to puc19 onto each side of the amplicon: HBP1_puc19F (5′-TCGGTACCCGGGGATCAAGTAGGAAAGTTTCGGTTGAGGAG-3′) and HBP1_puc19R (5′-TCGACTCTAGAGGATCAACTGAACAGATGACCGACTCTACC-3). We then cloned this into a linearized puc19 plasmid using Clontech’s In-Fusion HD Cloning Kit following the manufacturer’s protocol, transformed into Stellar Competent cells, grew up a single colony and extracted plasmid using the Zymo Research ZymoPURE Plasmid Midiprep Kit. We then re-linearized the puc19-HBP1 wild-type plasmid via PCR with puc19_HBP1-linF (5′-GTGGGGGATGGACTTGGCGTG-3′) and puc19-HBP1-linR (5′-CTCCTCAACCGAAACTTTCCTACTT-3′). We also amplified a small region around rs4730222, while mutating the SNP, using mut_insF (5′-AAGTAGGAAAGTTTCGGTTGAGGAG-3′) and mut_insR (5′-CCAAGTCCATCCCCCACGCTCTTTCGCCATTCATCGCG-3′). We then cloned the mutated insert into puc19-HBP1-wt using the In-Fusion HD Cloning Kit and grew up a single colony with the minor allele at rs4730222 flanked by 600–850 bp of homology on each side.
We transfected 1 million Saos-2 cells with 10 µg of our px458-rs4730222 guide and 10 µg of our donor library containing the minor allele using the Neon Transfection system as described above. Seventy-two hours post transfection, we performed FACS on a BD FACS Aria III to isolate ~150,000 GFP + cells (transfected with px458), which we then expanded. On day 10 post transfection, we extracted DNA and RNA, performed reverse transcription with Superscript III, and amplified the region surrounding rs4730222 from both DNA (using HBP1_5UTR_F_pu1 and HBP_DNA_Routside (5′-TAGGTGGGCAATCCTGGGAGAAGGTAC-3′)), and RNA (using HBP1_5UTR_F_pu1 and HBP_RNA_Routside (5′-TGCCAGATTCTGACTCACTATTTGC-3′)) in 50 µL reactions using KAPA HiFi 2x ReadyMix. We then purified the PCR reactions with a 1.5x AMPure cleanup, eluted in 50 uL, and used 1 µL in a nested reaction with pu1L (5′-CTAAATGGCTGTGAGAGAGCTCAG-3′) and HBP1_5UTR_R_pu1. Reactions were purified with a 1.5x AMPure cleanup, and flow-cell adapters and indexes were added using an indexed pu1_P5 primer and an indexed pu1_P7 primer. Libraries were spiked into a Miseq v2 300 cycle run. Reads were aligned to a fasta reference file using BWA mem, and the number of perfect reads coming from both alleles was quantified from both DNA and cDNA from each replicate.
Allelic imbalance of rs4730222 in OA patients’ chondrocytes
Cartilage tissue samples were obtained from OA patients who had undergone joint replacement surgery at the Newcastle upon Tyne NHS Foundation Trust hospitals. The Newcastle and North Tyneside Research Ethics Committee granted ethical approval for the collection, with each donor providing verbal and written informed consent (REC reference number 14/NE/1212). Our patient ascertainment criterion has been described in detail previously53,54. The cartilage was removed from the joint using a scalpel and was collected distal to the OA lesion. The tissue samples were stored frozen at −80 °C and ground to a powder using a Retsch Mixermill 200 (Retsch Limited) under liquid nitrogen. Nucleic acids were then extracted from the ground tissue using TRIzol reagent (Life Technologies) according to the manufacturer’s instructions, with the upper aqueous phase separated for RNA isolation, while the interphase and lower organic phase were used to isolate DNA. RNA was reverse transcribed using the SuperScript First-Strand cDNA synthesis kit (Invitrogen). Matched DNA and cDNA were amplified with KAPA HiFi 2x ReadyMix and SYBR Green and halted before plateauing. The primers sequences were as follows:
5′-CTAAATGGCTGTGAGAGAGCTCAGAGTCCGGGCTGCGGTCACATGATG-3′ and 5′-ACTTTATCAATCTCGCTCCAAACCAGCTACAAAAACCTGGCTGTCCAC-3′.
All samples were purified with a 1.5x AMPure cleanup following the manufacturer’s instructions and eluted in 50 µL Qiagen Elution Buffer. One microliter of purified product was then indexed for Illumina sequencing using an indexed pu1_P5 primer and an indexed pu1_P7 primer. Libraries were spiked into a Miseq v2 300 cycle run. Following our previously devised processing pipeline55, reads were aligned to a fasta reference file using BWA mem51, and the number of aligning reads coming from both alleles was quantified from both DNA and cDNA from each replicate. For statistical analysis, a Mann–Whitney U test was performed comparing DNA versus RNA abundances of the minor allele for the 18 values (9 for DNA and 9 for RNA; averaged over three replicates for each of nine patients).
Electrophoretic mobility shift assays (EMSAs) of rs4730222
Nuclear protein was extracted from SW1353 and Saos-2 cells as previously described56. For each allele of rs4730222, forward and reverse single-stranded DY682-labeled oligonucleotides (Eurofins MWG Operon), spanning 15 nt each side of the SNP (Supplementary Table 4), were annealed to generate double stranded probes. EMSAs were performed as previously described56.
Characterization of HBP1 rs4730222-containing isoforms
We designed the following set of primers to differentiate between different HBP1 isoforms: major (1stExonF: 5′-GTGTGGGAAGTGAAGACAAATCAGATGC-3′ and LastExonR: 5′-CTTCCACCTGTCACCAAGGATCACAC-3′), 5′-UTR (UTR_qPCR_F: 5′-CAGTCTCCGCCTTTCAACCTATG-3′ and UTR_qPCR_R: 5′-ATGAACTCGAGTGTAGAGTGCACAG-3′), Truncated (UTR_qPCR_F and Exon6_R: CCACCTCATTTTCACGGTAAGTAG-3′) and Full Len (UTR_qPCR_F and LastExonR). We performed technical triplicates for each qPCR using KAPA Robust 2x Hotstart Readymix with cDNA from wild-type SW1353 cells, letting the reaction go for 40 cycles. We then ran products on a gel, and differentiated between ENST00000497535 and ENST00000485846 based both on size and Sanger sequencing.
Lasso regression model to predict enhancer activity
For each candidate enhancer, we computed a total of 853 features derived from either (i) the sequence itself, or (ii) experimentally measured information, computed as a mean signal extracted from the corresponding region of the human genome (Supplementary Data 5, 6). The sequence-based features represent the conservation of the sequence, general G/C content, predicted chromatin state, and likelihood of binding to an assortment of transcription factors. In contrast, the experimentally derived features represent empirical measurements of chromatin/epigenetic state and binding to transcription factors. The features were derived from custom Perl scripts, the UCSC genome browser57, DeepSEA58, DeepBind59, and ChIP-Atlas60.
Right-skewed data such as ChIP-seq and CAGE signal were log-transformed to approximate a normal distribution, and each feature was then z-score normalized to scale the features similarly. This enabled a direct comparison of coefficients among features derived from the resulting linear models.
We trained a lasso regression model on each of 10-fold of the data55. A lasso regression model was chosen specifically because it employs an L1 regularization penalty, which leads to the selection of the fewest features that maximally explain the data. The strength of the regularization was controlled by a single λ parameter, which was optimized using 10-fold cross-validation on the entire data set. To evaluate the most relevant features selected, we trained a lasso regression model on the full data set and visualize the top 30 coefficients with the greatest magnitude (Supplementary Fig. 2B). A full table of the selected features and their coefficients are provided (Supplementary Data 6).
Breedveld, F. C. Osteoarthritis–the impact of a serious disease. Rheumatology 43, i4–i8 (2004).
Patwardhan, R. P. et al. High-resolution analysis of DNA regulatory elements by synthetic saturation mutagenesis. Nat. Biotechnol. 27, 1173–1175 (2009).
Patwardhan, R. P. et al. Massively parallel functional dissection of mammalian enhancers in vivo. Nat. Biotechnol. 30, 265–270 (2012).
Melnikov, A. et al. Systematic dissection and optimization of inducible enhancers in human cells using a massively parallel reporter assay. Nat. Biotechnol. 30, 271 (2012).
Arnold, C. D. et al. Genome-wide quantitative enhancer activity maps identified by STARR-seq. Science 339, 1074–1077 (2013).
Tewhey, R. et al. Direct identification of hundreds of expression-modulating variants using a multiplexed reporter assay. Cell 172, 1132–1134 (2018).
Ulirsch, J. C. et al. Systematic functional dissection of common genetic variation affecting red blood cell traits. Cell 165, 1530–1545 (2016).
Liu, S. et al. Systematic identification of regulatory variants associated with cancer risk. Genome Biol. 18, 194 (2017).
Vockley, C. M. et al. Massively parallel quantification of the regulatory effects of noncoding genetic variation in a human cohort. Genome Res. 25, 1206–1214 (2015).
Consortium, A. & Others arcOGEN Collaborators, Zeggini, E., Panoutsopoulou, K, Southam, L, Rayner, NW et al. Identification of new susceptibility loci for osteoarthritis (arcOGEN): a genome-wide association study. Lancet 380, 815–823 (2012).
Kerkhof, H. J. M. et al. A genome-wide association study identifies an osteoarthritis susceptibility locus on chromosome 7q22. Arthritis Rheum. 62, 499–510 (2010).
Day-Williams, A. G. et al. A variant in MCF2L is associated with osteoarthritis. Am. J. Hum. Genet. 89, 446–450 (2011).
Meulenbelt, I. et al. Identification of DIO2 as a new susceptibility locus for symptomatic osteoarthritis. Hum. Mol. Genet. 17, 1867–1875 (2008).
Meulenbelt, I. et al. Meta-analyses of genes modulating intracellular T3 bio-availability reveal a possible role for the DIO3 gene in osteoarthritis susceptibility. Ann. Rheum. Dis. 70, 164–167 (2011).
Styrkarsdottir, U. et al. Severe osteoarthritis of the hand associates with common variants within the ALDH1A2 gene and with rare variants at 1p31. Nat. Genet. 46, 498–502 (2014).
Evangelou, E. et al. The DOT1L rs12982744 polymorphism is associated with osteoarthritis of the hip with genome-wide statistical significance in males. Ann. Rheum. Dis. 72, 1264–1265 (2013).
Evangelou, E. et al. A meta-analysis of genome-wide association studies identifies novel variants associated with osteoarthritis of the hip. Ann. Rheum. Dis. 73, 2130–2136 (2014).
Miyamoto, Y. et al. A functional polymorphism in the 5′ UTR of GDF5 is associated with susceptibility to osteoarthritis. Nat. Genet. 39, 529–533 (2007).
den Hollander, W. et al. Genome-wide association and functional studies identify a role for matrix Gla protein in osteoarthritis of the hand. Ann. Rheum. Dis. 76, 2046–2053 (2017).
Panoutsopoulou, K. et al. Radiographic endophenotyping in hip osteoarthritis improves the precision of genetic association analysis. Ann. Rheum. Dis. 76, 1199–1206 (2017).
Castaño-Betancourt, M. C. et al. Novel genetic variants for cartilage thickness and hip osteoarthritis. PLoS Genet. 12, e1006260 (2016).
Yau, M. S. et al. Genome-wide association study of radiographic knee osteoarthritis in North American Caucasians. Arthritis Rheuma. 69, 343–351 (2017).
Evans, D. S. et al. Genome-wide association and functional studies identify a role for IGFBP3 in hip osteoarthritis. Ann. Rheum. Dis. 74, 1861–1867 (2015).
Valdes, A. M. et al. Genetic variation≥ in the SMAD3 gene is associated with hip and knee osteoarthritis. Arthritis Rheum. 62, 2347–2352 (2010).
Rodriguez-Fontenla, C. et al. Assessment of osteoarthritis candidate genes in a meta-analysis of nine genome-wide association studies. Arthritis Rheuma. 66, 940–949 (2014).
Casalone, E. et al. A novel variant in GLIS3 is associated with osteoarthritis. Ann. Rheum. Dis. 77, 620–623 (2018).
Zengini, E. et al. Genome-wide analyses using UK Biobank data provide insights into the genetic architecture of osteoarthritis. Nat. Genet. 50, 549–558 (2018).
Cotney, J. et al. The evolution of lineage-specific regulatory activities in the human embryonic limb. Cell 154, 185–196 (2013).
Herlofsen, S. R. et al. Genome-wide map of quantified epigenetic changes during in vitro chondrogenic differentiation of primary human mesenchymal stem cells. BMC Genom. 14, 105 (2013).
Raine, E. V. A., Wreglesworth, N., Dodd, A. W., Reynard, L. N. & Loughlin, J. Gene expression analysis reveals HBP1 as a key target for the osteoarthritis susceptibility locus that maps to chromosome 7q22. Ann. Rheum. Dis. 71, 2020–2027 (2012).
Luyten, F. P., Tylzanowski, P. & Lories, R. J. Wnt signaling and osteoarthritis. Bone 44, 522–527 (2009).
Berasi, S. P., Xiu, M., Yee, A. S. & Paulson, K. E. HBP1 repression of the p47phox gene: cell cycle regulation via the NADPH oxidase. Mol. Cell. Biol. 24, 3011–3024 (2004).
Scott, J. L. et al. Superoxide dismutase downregulation in osteoarthritis progression and end-stage disease. Ann. Rheum. Dis. 69, 1502–1510 (2010).
Liu, Y. et al. Chromatin accessibility landscape of articular knee cartilage reveals aberrant enhancer regulation in osteoarthritis. Sci. Rep. 19, 15499 (2018).
Thierry-Mieg, D., Thierry-Mieg, J. & NCBI/NLM/NIH. AceView: Gene:HBP1, a comprehensive annotation of human, mouse and worm genes with mRNAs or ESTsAceView. https://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.cgi?db=36a&c=Gene&l=HBP1 (2018).
Gee, F., Rushton, M. D., Loughlin, J. & Reynard, L. N. Correlation of the osteoarthritis susceptibility variants that map to chromosome 20q13 with an expression quantitative trait locus operating on NCOA3 and with functional variation at the polymorphism rs116855380. Arthritis Rheumatol. 67, 2923–2932 (2015).
Shepherd, C. et al. Functional characterisation of the osteoarthritis genetic risk residing at ALDH1A2 identifies rs12915901 as a key target variant. Arthritis Rheumatol. https://doi.org/10.1002/art.40545 (2018).
Fishilevich, S. et al. Genic insights from integrated human proteomics in GeneCards. Database. https://doi.org/10.1093/database/baw030 (2016).
Feng, H., Tillman, H., Wu, G., Davidoff, A. M. & Yang, J. Frequent epigenetic alterations in polycomb repressive complex 2 in osteosarcoma cell lines. Oncotarget 9, 27087–27091 (2018).
Kim, S. W. et al. Non-canonical Wnt signals are modulated by the Kaiso transcriptional repressor and p120-catenin. Nat. Cell Biol. 6, 1212–1220 (2004).
Loeser, R. F., Goldring, S. R., Scanzello, C. R. & Goldring, M. B. Osteoarthritis: A disease of the joint as an organ. Arthritis Rheum. 64, 1697–1707 (2012).
Pitsillides, A. A. & Beier, F. Cartilage biology in osteoarthritis–lessons from developmental biology. Nat. Rev. Rheumatol. 7, 654–663 (2011).
Lefebvre, V. & Bhattaram, P. Vertebrate skeletogenesis. Curr. Top. Dev. Biol. 90, 291–317 (2010).
Monteagudo, S. & Lories, R. J. Cushioning the cartilage: a canonical Wnt restricting matter. Nat. Rev. Rheumatol. 13, 670–681 (2017).
Lories, R. J., Corr, M. & Lane, N. E. To Wnt or not to Wnt: the bone and joint health dilemma. Nat. Rev. Rheumatol. 9, 328–339 (2013).
Zhu, M. et al. Inhibition of beta-catenin signaling in articular chondrocytes results in articular cartilage destruction. Arthritis Rheum. 58, 2053–2064 (2008).
Zhu, M. et al. Activation of β-Catenin Signaling in Articular Chondrocytes Leads to Osteoarthritis-Like Phenotype in Adult β-Catenin Conditional Activation Mice. J. Bone Miner. Res. 24, 12–21 (2009).
Sampson, E. M. et al. Negative regulation of the Wnt-beta-catenin pathway by the transcriptional repressor HBP1. EMBO J. 20, 4500–4511 (2001).
Wang, X., Hou, J., Quedenau, C. & Chen, W. Pervasive isoform‐specific translational regulation via alternative transcription start sites in mammals. Mol. Syst. Biol. 12, 875 (2016).
Reyes, A. & Huber, W. Alternative start and termination sites of transcription drive most transcript isoform differences across human tissues. Nucleic Acids Res. 46, 582–592 (2018).
Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Preprint at http://arxiv.org/abs/1303.3997 (2013).
Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308 (2013)
Southam, L. et al. An SNP in the 5′-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage. Hum. Mol. Genet. 16, 2226–2232 (2007).
Egli, R. J. et al. Functional analysis of the osteoarthritis susceptibility-associated GDF5 regulatory polymorphism. Arthritis Rheum. 60, 2055–2064 (2009).
Inoue, F. et al. A systematic comparison reveals substantial differences in chromosomal versus episomal encoding of enhancer activity. Genome Res. 27, 38–52 (2017).
Syddall, C. M., Reynard, L. N., Young, D. A. & Loughlin, J. The identification of trans-acting factors that regulate the expression of GDF5 via the osteoarthritis susceptibility SNP rs143383. PLoS Genet. 9, e1003557 (2013).
Karolchik, D. et al. The UCSC genome browser database: 2014 update. Nucleic Acids Res. 42, D764–D770 (2014).
Zhou, J. & Troyanskaya, O. G. Predicting effects of noncoding variants with deep learning-based sequence model. Nat. Methods 12, 931–934 (2015).
Alipanahi, B., Delong, A., Weirauch, M. T. & Frey, B. J. Predicting the sequence specificities of DNA- and RNA-binding proteins by deep learning. Nat. Biotechnol. 33, 831–838 (2015).
Oki, S. et al. ChIP-Atlas: a data-mining suite powered by full integration of public ChIP-seq data. EMBO Rep. 19, e46255 (2018).
The authors thank the Shendure and Loughlin labs, particularly J. Alexander, M. Gasperini, and S. Kim, for helpful discussions. This work was funded by grants from the National Institutes of Health (UM1HG009408, R01CA197139, R01HG006768) to J.S. J.C.K. was supported in part by 1F30HG009479 from the NHGRI. J.S. is an investigator of the Howard Hughes Medical Institute. S.J.R., C.S. and J.L. were supported by Arthritis Research UK (grant 20771), and by the Medical Research Council and Arthritis Research UK as part of the MRC-Arthritis Research UK Centre for Integrated Research into Musculoskeletal Aging (CIMA, grant references JXR 10641, MR/P020941/1 and MR/R502182/1).
The authors declare no competing interests.
Journal peer review information: Nature Communications thanks Stein Aerts and the other anonymous reviewer(s) for their contribution to the peer review of this work.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Klein, J., Keith, A., Rice, S.J. et al. Functional testing of thousands of osteoarthritis-associated variants for regulatory activity. Nat Commun 10, 2434 (2019). https://doi.org/10.1038/s41467-019-10439-y
DNA variants affecting the expression of numerous genes in trans have diverse mechanisms of action and evolutionary histories
PLOS Genetics (2019)
Recommendations for the collection and use of multiplexed functional data for clinical variant interpretation
Genome Medicine (2019)
Tissue Engineering Part A (2019)